Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly FCF Margin came in at 24216.95% in Q4 2025, down 1638153.0% YoY from N/an in Q4 2024, and down 209.07% on a QoQ basis from 7835.42% in Q4 2024.
Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of FCF Margin data on file, last reported at 24216.95% in Q4 2025.
- Quarterly FCF Margin fell 1638153.0% year-over-year to 24216.95% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 10300.0% (up 82381.0% YoY) and the FY2025 annual result came in at 87288.14%, down 7616433.0% from the prior year.
- FCF Margin slipped to 24216.95% in Q4 2025, from 7835.42% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 38.68% in Q3 2022 to a low of 24216.95% in Q4 2025.
- A 5-year average of 4004.93% and a median of 1714.77% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 690081 bps — and 2025, when it tumbled 1638153 bps.
- Tracing AVTX's FCF Margin over 5 years: stood at 7351.14% in 2021, then surged by 94 bps to 450.33% in 2022, then declined by 8 bps to 484.41% in 2023, then sank by 1518 bps to 7835.42% in 2024, then sank by 209 bps to 24216.95% in 2025.
- The last three FCF Margin figures came in at 24216.95% (Q4 2025), 7835.42% (Q4 2024), and 4629.32% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24,216.95% |
| Dec 31, 2024 | -7,835.42% |
| Sep 30, 2024 | -4,629.32% |
| Dec 31, 2023 | -484.41% |
| Sep 30, 2023 | -2,896.61% |
| Jun 30, 2023 | -1,714.77% |
| Mar 31, 2023 | -2,149.47% |
| Dec 31, 2022 | -450.33% |
| Sep 30, 2022 | 38.68% |
| Jun 30, 2022 | -1,212.58% |
| Mar 31, 2022 | -1,369.74% |
| Dec 31, 2021 | -7,351.14% |
| Sep 30, 2021 | -1,353.26% |
| Jun 30, 2021 | -571.89% |
| Mar 31, 2021 | -3,876.74% |
| Dec 31, 2020 | -964.46% |
| Sep 30, 2020 | -1,068.41% |
| Jun 30, 2020 | -639.39% |
| Mar 31, 2020 | -208.39% |
| Dec 31, 2019 | -42.04% |